{
  "id": 19187442,
  "title": "레타트루타이드 3상 임상 결과와 분자 구조 탐색의 새로운 방법",
  "url": "https://urgent.news/2026/11/09/3-19187442",
  "topic": "tech",
  "section": "Tech",
  "published": "2026-11-09T18:01:41.000Z",
  "source": {
    "name": "Dev.to",
    "slug": "dev-to",
    "url": "https://dev.to/ashish_624379625242c5d263/retateurutaideu-3sang-imsang-gyeolgwawa-bunja-gujo-tamsaegyi-saeroun-bangbeob-2bp5"
  },
  "original_language": "ko",
  "account": "Medical Xpress recently reported that two Phase 3 clinical trials led by Northwestern University involving over 1,000 participants each have shown that the experimental weight-loss drug retatrutide can reduce body weight in patients with osteoarthritis (OA) of the knee by an average of 25% and significantly improve pain. Retatrutide is a triple agonist that simultaneously acts on the glucagon receptor (GCGR), GLP-1 receptor (GLP-1R), and GIP receptor (GIPR). While the clinical impact of this 25% weight reduction is emphasized, the structural and molecular aspects of retatrutide's mechanism of action are often overlooked. Triple agonists, such as retatrutide, work by selectively binding to three different Class B GPCR subtypes (GCGR, GLP-1R, and GIPR), which share a common dimeric 7-transmembrane domain architecture but differ in their pocket environments, peptide sequence preferences, and allosteric coupling networks. Traditional 2D structural representations fail to capture the nuances of these differences, making it challenging to visualize and compare the binding pockets of these three receptors simultaneously. To address this limitation, NexoPeek, a VR-based molecular visualization and analysis tool developed by Seven Sportz, allows users to interact with and compare the three receptor structures in 3D space. NexoPeek enables users to load molecular files, switch between different visualization styles (cartoon, ball-and-stick, spacefill CPK, surface, B-factor heat map, and tubetrace), and perform various tasks such as pocket interaction analysis, foldseek structural alignment, hydrogen bond inspection, trigger-pick distance measurement, and residue highlighting. These features provide a more intuitive understanding of retatrutide's unique triple agonist design and its effects on the binding pockets of the three GPCRs, ultimately contributing to the drug's clinical success in treating OA-related pain and weight management.",
  "summary": "레타트루타이드 3상 임상 결과와 분자 구조 탐색의 새로운 방법 2026년 11월 Medical Xpress 보도에 따르면, 노스웨스턴 대학 주도 두 건의 3상 임상시험(참가자 1,000명 이상)에서 실험적 비만 치료제 레타트루타이드(retatrutide)가 무릎 골관절염(OA) 환자의 체중을 평균 25% 감소시키고 통증을 유의미하게 개선했습니다. 레타트루타이드는 GCGR(글루카곤 수용체), GLP-1R, GIPR 세 수용체에 동시 작용하는 삼중 작용제(triple agonist)입니다. 왜 이 결과가 구조생물학적으로 중요한가 임상 뉴스는 대개 \"체중 25% 감소\"라는 숫자에서 멈춥니다. 그런데 개발자나 계산 구조생물학 쪽에서 이 뉴스를 읽으면 다른 질문이 먼저 떠오릅니다. 하나의 리간드가 왜 세 개의 서로…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Hankyoreh",
        "title": "30,000 in Denmark hold simultaneous strike, protest \"Why spend money on war and cut youth welfare?\"",
        "url": "https://urgent.news/2026/11/05/3",
        "published": "2026-11-05T03:58:51.000Z"
      },
      {
        "outlet": "The Asahi Shimbun",
        "title": "In Shizuoka Prefecture, three people were injured. A late-night emergency earthquake alert caused a fisher to \"panic\".",
        "url": "https://urgent.news/2026/11/08/3",
        "published": "2026-11-08T03:40:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}